Quest Diagnostics (DGX) Common Equity (2009 - 2026)

Quest Diagnostics has disclosed Common Equity across 18 years of filings, most recently posting $7.8 billion for Q2 2026.

• In Q2 2026, Common Equity rose 7.63% year-over-year to $7.8 billion; the TTM figure through Jun 2026 stood at $7.8 billion (up 7.63% YoY), while the FY2025 annual figure was $7.2 billion, up 5.77% from the prior year.
• Common Equity came in at $7.8 billion for Q2 2026 at Quest Diagnostics, up from $7.7 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $7.8 billion in Q2 2026 to a low of $5.9 billion in Q4 2022.
• Average Common Equity over 5 years is $6.7 billion, with a median of $6.6 billion recorded in 2024.
• Year-over-year, Common Equity retreated 8.53% in 2022 and rose 10.11% in 2026.
• Over 5 years, Common Equity stood at $5.9 billion in 2022, then grew by 6.95% to $6.3 billion in 2023, then gained by 7.43% to $6.8 billion in 2024, then grew by 5.77% to $7.2 billion in 2025, then increased by 8.51% to $7.8 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $7.8 billion in Q2 2026, $7.7 billion in Q1 2026, and $7.2 billion in Q4 2025.